In the United States U. It is often mild, and most people make a full recovery, after which they are immune and therefore protected from the virus in the future. However, if it progresses, symptoms can be severe or life-threatening. The liver of a person infected with hepatitis B swells. Severe damage can result. HBV infection can become chronic. This can lead to complications, including scarring of the liver, or cirrhosis. It can also cause a type of cancer known as hepatocellular carcinoma. In , , deaths worldwide were linked to HBV, mostly as a result of complications such as these.
In the U. There is not currently a cure for HBV. However, the incidence rate has dropped in countries where the vaccine is available, and this vaccine is 95 percent effective against the infection. HCV can lead to liver damage and swelling. Around 1 in 4 people with HCV get cirrhosis, and this can lead to liver cancer. Donated blood is now tested for HCV, but people who received organ transplants or blood donations before testing became part of the donation process may be at risk.
Other at-risk groups include healthcare workers who are exposed to sharps, users of intravenous drugs, and infants born to mothers with HCV. The number of cases of HCV in the U. However, the CDC estimate that 33, infections occurred in , including those not reported. Some types and cases of hepatitis can heal without intervention, but sometimes it can progress to scarring of the liver, or cirrhosis.
There is no specific treatment for HAV. The doctor will advise the patient to abstain from alcohol and drugs during the recovery. Most patients with hepatitis A will recover without intervention. A patient with HBV needs to rest and abstain completely from alcohol. The doctor may prescribe an antiviral agent called interferon, or other antiviral suppressive therapies. Some directed antivirals and combination therapies are now available to treat the hepatitis C virus based on its subtype. These treatments target viral replication and prevent the virus from being able to reproduce.
When taken correctly, the cure rate is very high. Many people with hepatitis experience either mild or no symptoms. When symptoms appear, they can do so from 15 to days after infection. This applies to all types of hepatitis. The initial phase of hepatitis is called the acute phase. The symptoms are similar to mild flu , and may include :. The acute phase is not usually dangerous, but in certain people, it can result in acute liver failure and death.
It may also progress to a chronic infection. As the disease progresses, chronic hepatitis can lead to progressive liver failure, resulting in jaundice, swelling of the lower extremities, confusion, and blood in the feces or vomit. The following may occur :. Patient outcomes after the acute phase depend on various factors, especially the type of hepatitis.
Management of Hepatitis C: Evaluating Suitability for Drug Therapy - American Family Physician
Some people will not know they have chronic hepatitis until liver failure occurs. As the symptoms of the different types of hepatitis are similar, the type and severity of hepatitis may only be diagnosed through laboratory tests. A doctor will perform a physical examination and ask for a medical history to assess whether a patient has been exposed to a likely cause of hepatitis. If a patient recently traveled abroad, they may have HAV. If they have had unprotected sex, they may have HBV. Hepatitis A is caused by consuming food or water infected with the hepatitis A virus HAV , often while traveling abroad.
The virus can also be transmitted through anal-oral contact during sex or by injecting drugs. Hepatitis B is caused by the hepatitis B virus HBV and is spread through contact with infected blood, semen, and some other body fluids. It can be a sexually transmitted disease STD. Hepatitis C mostly results from percutaneous infection, occurring when the HCV virus gets under the skin.
It is usually spread through injected narcotics, needle-stick injuries, and a lack of infection control in healthcare settings. HCV cannot be caught from contact with feces, and sexual transmission is less common than in other types. Alcohol, medicines, obesity , and chemical exposure do not cause types A, B, or C, but they may aggravate inflammation and make symptoms worse.
Hepatitis can be dangerous and difficult to treat, so people are advised to take precautions against possible infection. As this is often passed on through the transfer of infected bodily fluids, the following steps can help prevent HCV transmission:. Hepatitis A and C are curable, but hepatitis B is only preventable by vaccine. A cure is still under development. Hepatitis A: This type of hepatitis will normally resolve in 2 months without leaving any long-term effects. A person with HAV will usually be immune to hepatitis A for the rest of their life.
Hepatitis B: Most adults infected with the HBV virus recover within 90 days and achieve lifelong immunity. However, 90 percent of infants , 20 percent of older children, and 5 percent of adults will develop a chronic infection and develop severe health problems, such as liver cancer and cirrhosis. Hepatitis C: This becomes a lifelong infection in 70 to 85 percent of people that have the HCV virus.
Hepatitis C is fatal in between 1 and 5 percent of people. The infection can now be cured, and 15 to 25 percent of people with HCV clear the infection without treatment.
- Advances in Irrigation Agronomy: Fruit Crops!
- Hepatitis B - Diagnosis and treatment - Mayo Clinic.
- Chronic viral hepatitis.
Article last updated by Adam Felman on Fri 24 November All references are available in the References tab. Bhatia, H. Journal of Pharmacology and Pharmacotherapeutics, 5 4 , Hepatitis A. Hepatitis A, B, and C: Learn the differences. Hepatitis B. Hepatitis C FAQs for health professionals. Hepatitis B: fact sheet. Menche, N. Poordad, F.
The New England Journal of Medicine, , Rocco, A. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus [abstract].
Want to read more?
Gut, 62 , BMC Microbiology , Journal of Virology , 86 18 Cell Reports , 27; Longitudinal changes in HIV-1 specific T-cell quality associated with viral load dynamic. Journal of Clinical Virology , 55 2 Hepatology , 56 3 Journal of Infectious Diseases , 11 Low-dose adenoviral HBV genome transfer establishes persistent infection in immune competent mice.
Gastroenterology , 11 Norovirus GII. Infection, Genetics and Evolution , , TLR2-mediated innate immune response in human non-parenchymal liver cells towards adeno-associated viral AAV vectors. Hepatology , Jan;55 1 PLOS One , 6 10 : e Gastroenterology , accepted for publication. Hepatitis B Virus X protein is essential to initiate and maintain virus replication after infection. J Hepatology , Mar 1. Sequential control of hepatitis B virus in a mouse model of acute, self-resolving hepatitis B. Journal of Viral Hepatitis , 18 3 Apoptosis of hepatitis B virus infected hepatocytes prevents release of infectious virus.
Journal of Virology , 84 22 Neighbor of Punc E11, a novel onco-fetal marker for hepatocellular carcinoma. Int J of Cancer , July 23 [Epub ahead of print]. HBV replication in primary macaque hepatocytes: crossing the species barrier towards a new small primate model. Hepatoloy , Jun;51 6 MVA-nef induces HIVspecific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Gene Therapy , in press. Bioluminescence imaging allows measuring CD8 T cell function 1 in the liver. Hepatology , Isolated norovirus GII. J Med Virol. Z Gastroenterol. J Med Virology , — Hepatic Bax-inhibitor BI -1 inhibits IRE1a and protects from obesity-associated insulin resistance and glucose intolerance. J Biol Chem. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus.
Chronic Viral Hepatitis: Diagnosis and Therapeutics
J Viral Hepatitis Aug;15 Suppl Antimicrob Agents Chemotherapy , 52 7 Gastroenterology , Cellular Micobiology , Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. Bohne F, Protzer U. Adoptive T-cell therapy as a therapeutic option in chronic viral hepatitis. Viral Hepatitis , 14, Suppl 1: German guidelines on diagnosis and therapy of hepatitis B. Dtsch Med Wochenschr. Gastroenterologie , Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virology , Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection.
Eur J Gastroenterol Hepatol. Journal of Virology , Virology , The Tet-system allows tight control and liver-specific gene expression in vivo following adenoviral gene transfer into mice. Gene Therapy , Inhibition of cellular proteasome activities enhances hepadnaviral replication in a HBx dependent manner. Hepatitis B virus vectors allow elimination of viral gene expression and insertion of foreign promoters. Human Gene Therapy , Construction of recombinant adenoviruses that produce infectious hepattis B virus.
Methods in Molecular Medicine , Presence of replicating virus in recombinant hepadnavirus stocks results from homologous recombination and can be eliminated be the use of a packaging cell line. Journal of Virology , 77 5 : Journal of Medical Virology , Liver macrophages release mediators after endotoxin stimulation that inhibit an early step in hepadnavirus replication. Journal of Virology , 74 12 : Interferon gene transfer by a novel hepatitis B virus vector efficiently suppresses wildtype-virus infection.
PNAS , Characterization of cytotoxic T-cell response in HIV infected patients and seronegative high-risk contact persons. Journal of Infectious Diseases , Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation.
Hepatology , 27 1 : A pretransplant infection with precore mutants of Hepatitis B Virus does not influence the outcome of orthotopic liver transplantation in patients on high-dose anti-HBs immuno-prophylaxis. Hepatology , 26 2 : Gastroenterology ; 3 : Living in the Liver. Nature Reviews in Immunology , Microbial Biotechnology , Mar;5 2 Immune control of Hepatitis B Virus.
Digestive Diseases : Can engineered "designer" T cells out-smart chronic hepatitis B? Gene Therapy , 17 10 Control of Hepatitis B virus at the level of transcription. J Viral Hepatitis, , Aug;17 8 Hepatitis Viruses. In: Kessler HH ed. Antiviral gene therapy. Handb Exp Pharmacol.
In: Protzer U , Weber O eds.
Comparative Hepatitis. Infektionserkrankungender Leber. In: Mertes, Marre. Klinische Infektiologie. Transfer of HBV genomes into mice. In: Roggendorf M, v. In: Doerr DW ser. Karger AG, Basel, Switzerland, Construction of recombinant adenoviruses that produce infectious HBV. In: R. Hamatke, J. Lau eds. II , Chapter 18, pg Walker ser. Methods in Molecular Medicine. The Humana Press Inc. Protzer U , Schaller H. Immune Escape of Hepatitis B Viruses. Virus Genes , Protzer , B.